A woman wearing a hijab, glasses, a white lab coat, and blue gloves working with laboratory equipment, possibly conducting an experiment or research.
Gradient abstract background transitioning from black and pink to orange and yellow.
Gray octagonal shape with a dark center and blue outline.

Phage Australia takes a personalised, data-driven approach to phage therapy.

For phage therapy to be available to all Australians who need it, we must first secure its approval as a medicine by demonstrating successful outcomes.

STAMP: a unique phage therapy trial

STAMP stands for Standardised Treatment and Monitoring Protocol for Adults and Paediatric Patients. a

a STAMP is endorsed by ASID, The Australasian Society for Infectious Diseases, the peak professional body for infectious diseases and clinical microbiology in Australasia.

The STAMP protocol is unlike other commercial or investigator-initiated clinical trials where a specific therapy has been produced/manufactured by the 'sponsor' of the trial. In STAMP, it is not the phages themselves being studied. Rather, STAMP is evaluating the clinical protocol for administering and monitoring phage therapy. In other words, STAMP looks at the process, not the product. STAMP allows us to treat more patients with personalised phages, without sacrificing the standardised dosing and outcome monitoring that comes with clinical trials.

Why is it important to study process over product?

In STAMP, both the phages and the infection sites vary. This approach ensures that the phages are always customised to target the patient’s specific bacterial infection.

How are the phages regulated in Australia?

In Australia, phage therapy can be accessed under the STAMP protocol which is regulated through the Therapeutic Goods Administration's Special Access Scheme.

Recent STAMP milestones

Logo featuring a geometric design of hexagons forming a star shape, in shades of teal and navy blue, with a small trademark symbol in the bottom right corner.

STAMP endorsed by all clinicians and researchers within the Phage Australia network

Logo for the Australasian Society for Infectious Diseases featuring a stylized molecular structure in blue, pink, red, and yellow on a dark background.

STAMP endorsed by ASID, the Australasian Society for Infectious Diseases, as well as its paediatric arm

Logo of the Australian New Zealand Clinical Trials Registry with a checkmark.

STAMP approved by Australia’s national ethics committee in December 2021

Icon of a magnifying glass with a person inside, symbolizing search or investigation of a person.

STAMP registered as a clinical trial in Australia and New Zealand (ACTRN 12621001526864)

Line drawing of three people, two men and one woman, standing side by side, with the woman in the middle.

STAMP begins enrolling patients January 2022

Outline of a girl with a ponytail, wearing a dress, icon style, on a dark blue hexagonal background.

STAMP doses first patient with locally produced phages at Westmead in October 2022

Icon of multiple people standing behind a single person, representing a group or community.

STAMP treated 28 patients